Table 1 Summary of TP53 variations for 204 colorectal carcinoma patients
From: Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer
|  | Total n = 149 | Missense n = 108 | Nonsense n = 23 | Frameshift n = 18 |
|---|---|---|---|---|
Functional domains | ||||
 Transactivation | 0 | 0 | 0 | 0 |
 Proline rich region | 3 | 0 (0%) | 0 (0%) | 3 (16.7%) |
 DNA binding region | 129 | 106 (98.1%) | 10 (43.5%) | 13 (72.2%) |
Nuclear localization signalling | 6 | 0 (0%) | 6 (26.1%) | 0 (0%) |
 Tetramerization | 9 | 1 (0.9%) | 7 (30.4%) | 1 (5.6%) |
 Regulatory | 2 | 1 (0.9%) | 0 (0%) | 1 (5.6%) |
Sub-regions of DB domain | ||||
 L2 | 31 | 28 (25.9%) | 1 (4.3%) | 2 (11.1%) |
 L3 | 22 | 20 (18.5%) | 1 (4.3%) | 1 (5.6%) |
 LSH | 31 | 31 (28.7%) | 0 (0%) | 0 (0%) |
 Other | 65 | 29 (26.9%) | 21 (91.3%) | 15 (83.3%) |
Exons | ||||
 Exon4 | 9 | 1 (0.9%) | 1 (4.3%) | 7 (38.9%) |
 Exon5 | 36 | 33 (30.6%) | 1 (4.3%) | 2 (11.1%) |
 Exon6 | 22 | 12 (11.1%) | 7 (30.4%) | 3 (16.7%) |
 Exon7 | 26 | 24 (22.2%) | 0 (0%) | 2 (11.1%) |
 Exon8 | 44 | 35 (32.4%) | 7 (30.4%) | 2 (11.1%) |
 Exon9 | 1 | 0 (0%) | 1 (4.3%) | 0 (0%) |
 Exon10 | 10 | 2 (1.9%) | 6 (26.1%) | 1 (5.6%) |
 Exon11 | 2 | 1 (0.9%) | 0 (0%) | 1 (5.6%) |